SCHEMBL25091062

SCHEMBL25091062

Cn1nc(C(C)(C)C)c2ccc(C(C)(C)C)nc21

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 1/20 0.43
HCRTR2 O43614 1/20 0.43
NPSR1 Q6W5P4 2/20 0.34
KDM4E B2RXH2 3/20 0.33
ALDH1A1 P00352 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
GRN P28799 1/20 0.32
SORT1 Q99523 1/20 0.32
SSTR4 P31391 1/20 0.32
GAA P10253 1/20 0.31
MAPT P10636 1/20 0.31
MAPK1 P28482 1/20 0.31
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30
NR1H2 P55055 1/20 0.30
NR1H3 Q13133 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22358073 0.84 ADORA2A (0.38) HCRTR1HCRTR2NPSR1KDM4EALDH1A1
SCHEMBL31298626 0.81 HCRTR1 (0.40) HCRTR1HCRTR2NPSR1
SCHEMBL12299465 0.71 SSTR4 (0.50) HCRTR1HCRTR2NPSR1KDM4EL3MBTL1
SCHEMBL25091063 0.71 HCRTR1 (0.38) HCRTR1HCRTR2NPSR1KDM4EL3MBTL1
SCHEMBL25091051 0.70 HCRTR1 (0.33) HCRTR1HCRTR2NPSR1
SCHEMBL25091049 0.70 NPSR1 (0.36) HCRTR1HCRTR2NPSR1
SCHEMBL25091056 0.68 NPC1 (0.36) HCRTR1HCRTR2NPSR1KDM4EALDH1A1
SCHEMBL25566705 0.68 CRBN (0.57)
SCHEMBL18538064 0.68 ADORA2A (0.41) HCRTR1HCRTR2NPSR1KDM4EALDH1A1
SCHEMBL23660941 0.67 TRPA1 (0.35) NPSR1KDM4EL3MBTL1GRNSORT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230060334-A1 COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 C4 THERAPEUTICS, INC. (US) 2023-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230060334-A1 COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 BRD9, BRD1, BRWD1 HCRTR1 4593/4885HCRTR2 4706/4885NPSR1 4462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.